RxDoctor Payments Data

Vicki Deweese

Nurse Practitioner · Dalton, GANPI 1164411559

Payments from drug & device makers

$8,189in general payments, 2019–2025

Across 454 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Neurocrine Biosciences, Inc.$986
  • AbbVie$949
  • Supernus Pharmaceuticals, Inc.$891
  • Otsuka America Pharmaceutical, Inc.$610
  • Alkermes, Inc.$536
  • plus $3K from 17 others

What the payments were for

  • Food & beverage$8,189100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,189 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$20,075
Medicare patients
51
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl53$76,545
CaplytaLumateperone Tosylate24$38,095
TrintellixVortioxetine Hydrobromide59$32,029
RexultiBrexpiprazole19$30,733
AuvelityDextromethorphan Hbr/Bupropion22$22,168
Lurasidone Hcl50$2,697
Quetiapine Fumarate130$2,650
Ziprasidone Hcl29$2,629
Duloxetine Hcl85$1,709
Buspirone Hcl117$1,636
Trazodone Hcl96$1,410
Oxcarbazepine39$1,338
Aripiprazole29$1,336
Fluoxetine Hcl70$1,327
Triazolam17$1,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$949$76,54553 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,390$38,09524 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$493$32,02959 claims
Otsuka America Pharmaceutical, Inc.Rexulti$610$30,73319 claims
Axsome Therapeutics, Inc.Auvelity$78$22,16822 claims
Almatica Pharma LLCSertraline Hcl$83$26743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →